靶向激活的KIT信号通路用于黑色素瘤治疗。 - Suppr

Suppr

超能文献

Targeting activated KIT signaling for melanoma therapy.

作者信息

Bastian Boris C, Esteve-Puig Rosaura

机构信息

University of California at San Francisco, San Francisco, CA.

出版信息

J Clin Oncol. 2013 Sep 10;31(26):3288-90. doi: 10.1200/JCO.2013.50.3227. Epub 2013 Aug 12.

DOI:10.1200/JCO.2013.50.3227

PMID:23940224

Abstract

摘要

相似文献

Targeting activated KIT signaling for melanoma therapy.

J Clin Oncol. 2013 Sep 10;31(26):3288-90. doi: 10.1200/JCO.2013.50.3227. Epub 2013 Aug 12.

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.

Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7. doi: 10.1111/j.1755-148X.2009.00593.x.

KIT and Melanoma: Biological Insights and Clinical Implications.

Yonsei Med J. 2020 Jul;61(7):562-571. doi: 10.3349/ymj.2020.61.7.562.

Advances in targeted therapy for melanoma.

Clin Adv Hematol Oncol. 2010 Sep;8(9):619-27.

Therapeutic implications of KIT in melanoma.

Cancer J. 2012 Mar-Apr;18(2):137-41. doi: 10.1097/PPO.0b013e31824b2404.

Imatinib in melanoma: a selective treatment option based on KIT mutation status?

J Clin Oncol. 2007 Mar 1;25(7):e9. doi: 10.1200/JCO.2006.08.9664.

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Exp Dermatol. 2011 Dec;20(12):1030-2. doi: 10.1111/j.1600-0625.2011.01385.x.

Complete response in a melanoma patient treated with imatinib.

J Laryngol Otol. 2012 Jun;126(6):638-40. doi: 10.1017/S0022215112000527.

c-KIT in uveal melanoma: big fish or red herring?

Arch Ophthalmol. 2009 May;127(5):695-7. doi: 10.1001/archophthalmol.2009.49.

[Gene abnormalities in melanoma and signal transduction antagonists].

Gan To Kagaku Ryoho. 2013 Apr;40(4):453-7.

引用本文的文献

Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?

Front Oncol. 2021 Nov 4;11:775100. doi: 10.3389/fonc.2021.775100. eCollection 2021.

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma.

Cancers (Basel). 2020 Apr 25;12(5):1062. doi: 10.3390/cancers12051062.

The Oncogenic Signaling Pathways in -Mutant Melanoma Cells are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands.

Cells. 2019 Oct 18;8(10):1274. doi: 10.3390/cells8101274.

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

CA Cancer J Clin. 2019 Jul;69(4):305-343. doi: 10.3322/caac.21560. Epub 2019 May 22.

Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas.

Oncotarget. 2017 Nov 25;8(65):109457-109467. doi: 10.18632/oncotarget.22691. eCollection 2017 Dec 12.

Molecular genetic and immunotherapeutic targets in metastatic melanoma.

Virchows Arch. 2017 Aug;471(2):281-293. doi: 10.1007/s00428-017-2113-3. Epub 2017 Mar 29.

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.

Int J Mol Sci. 2017 Mar 28;18(4):715. doi: 10.3390/ijms18040715.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Cancer. 2017 Jul 15;123(14):2688-2697. doi: 10.1002/cncr.30663. Epub 2017 Mar 23.

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.

Oncotarget. 2016 Jul 19;7(29):45916-45925. doi: 10.18632/oncotarget.10001.

Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.

Oncogene. 2016 Sep 22;35(38):5070-7. doi: 10.1038/onc.2016.39. Epub 2016 Mar 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验